Joining this wonderful webinar is Francesco Passiglia, Thoracic Oncologist at San Luigi Hospital, Orbassano, Turin, and Associate Professor in the Department of Oncology at the University of Turin, Italy.
Targeted cancer genomic profile-guided cancer therapy is improving patient outcomes. It has been proven that patients treated first-line based on their genomic profile have a 22% higher probability of survival 2 years from diagnosis. The number of biomarkers associated with targeted treatments continues to increase, and is expected to reach 21 just in non-small cell lung cancer (NSCLC) in 2025. However, according to real-world data analyses of clinical gaps in management of patients with NSCLC, turnaround time to complete actionable biomarker results is one of the main barriers to access precision oncology treatments, especially in NSCLC.
In this webinar, Francesco Passiglia summarises the complex landscape of NSCLC precision oncology biomarkers and treatment. She shares how San Luigi Hospital is addressing this barrier with the help of in-house rapid next generation sequencing to deliver complete actionable results in as fast as 3 days, enabling clinicians to make timely and informed therapy decisions.
This webinar is sponsored by Thermo Fisher.
